Requires investigating of critical prescription drug pricing; provides for civil penalties and private actions for certain critical prescription drug pricing.

New York Assembly Bill A10467, introduced on March 6, 2026, aims to regulate the pricing of essential prescription drugs. It mandates the Superintendent of Insurance to investigate instances where the price of a critical prescription drug increases over a 12-month period by more than the cost of living index. If such an unjustified price increase is found, the bill allows for civil penalties, including fines up to $5,000 per offense or double the economic gain from the price hike. Additionally, the bill defines 'critical prescription drugs' as those necessary to prevent or treat life-threatening conditions.

Positive media analysis is being generated.

Although direct media critiques of Bill A10467 are not found, analogous legislation has faced opposition. For example, New York's SAFE for Kids Act, intended to regulate children's exposure to social media content, encountered criticism over potential privacy infringements and free speech concerns. Similarly, the prescription drug pricing bill might attract negative reactions from pharmaceutical companies and free-market advocates who could argue that such regulations interfere with business operations and market dynamics.